Annovis Bio
ANVS
35 hedge funds and large institutions have $9.5M invested in Annovis Bio in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 7 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
68% more capital invested
Capital invested by funds: $5.67M → $9.5M (+$3.83M)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
13% more funds holding
Funds holding: 31 → 35 (+4)
0.22% more ownership
Funds ownership: 8.81% → 9.03% (+0.22%)
72% less call options, than puts
Call options by funds: $3.33M | Put options by funds: $12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$962K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$494K |
| 3 |
A
AlphaQuest
New York
|
+$431K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$295K |
| 5 |
D.E. Shaw & Co
New York
|
+$229K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$576K |
| 2 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
-$176K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$115K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$104K |
| 5 |
Morgan Stanley
New York
|
-$38.9K |
ANVS Hedge Fund Activity: Q3 2024 in Review
35 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q3 2024, worth a combined $9.5M — up 68% from $5.67M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ANVS positions and 7 closed out — a net gain of 4 holders — while 12 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $962K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $576K sold.
- 35 institutional investors held Annovis Bio (ANVS) as of Q3 2024, up from 31 in Q2 2024.
- Funds reported $9.5M of Annovis Bio stock for Q3 2024, up 68% quarter-over-quarter.
- 11 funds opened new Annovis Bio positions in Q3 2024 and 7 closed out, a net change of +4 holders.
- The largest Annovis Bio buyer in Q3 2024 was Citadel Advisors, an estimated $962K added.
- The largest Annovis Bio seller in Q3 2024 was Adage Capital Partners, an estimated $576K sold.
Based on aggregated 13F filings for Q3 2024.